[Current status and challenges of AML treatment with FLT3 inhibitors].

Abstract excerpt

FLT3 mutation is one of the most frequent genetic mutations in AML, identified in approximately 30% of patients, and FLT3-ITD mutation is considered a poor prognostic factor. Based on these molecular and clinical backgrounds, FLT3 mutations are considered promising therapeutic targets in AML, and intensive development of targeted therapeutics has been ongoing for more than two decades. Recently, combination of...

Topics

• fms-Like Tyrosine Kinase 3
• Humans
• Leukemia, Myeloid, Acute
• Mutation
• Protein Kinase Inhibitors
• Drug Resistance, Neoplasm